U.S. Physical Therapy, Inc. (USPH) Director Mark J. Brookner Sells 2,000 Shares

U.S. Physical Therapy, Inc. (NYSE:USPH) Director Mark J. Brookner sold 2,000 shares of the stock in a transaction on Monday, November 5th. The shares were sold at an average price of $113.75, for a total value of $227,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark J. Brookner also recently made the following trade(s):

  • On Friday, September 21st, Mark J. Brookner sold 2,500 shares of U.S. Physical Therapy stock. The shares were sold at an average price of $116.00, for a total value of $290,000.00.
  • On Friday, September 7th, Mark J. Brookner sold 625 shares of U.S. Physical Therapy stock. The shares were sold at an average price of $128.50, for a total value of $80,312.50.
  • On Thursday, August 23rd, Mark J. Brookner sold 4,375 shares of U.S. Physical Therapy stock. The shares were sold at an average price of $116.82, for a total value of $511,087.50.

NYSE USPH opened at $114.46 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 1.93 and a debt-to-equity ratio of 0.26. U.S. Physical Therapy, Inc. has a 12-month low of $64.45 and a 12-month high of $129.65. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 55.03, a price-to-earnings-growth ratio of 3.95 and a beta of 1.19.

U.S. Physical Therapy (NYSE:USPH) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.06. The business had revenue of $113.10 million during the quarter, compared to analyst estimates of $112.79 million. U.S. Physical Therapy had a net margin of 5.58% and a return on equity of 17.64%. U.S. Physical Therapy’s revenue was up 9.8% on a year-over-year basis. Sell-side analysts predict that U.S. Physical Therapy, Inc. will post 2.56 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 7th. Shareholders of record on Friday, November 9th will be issued a $0.23 dividend. The ex-dividend date is Thursday, November 8th. This represents a $0.92 annualized dividend and a yield of 0.80%. U.S. Physical Therapy’s dividend payout ratio (DPR) is presently 44.23%.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bessemer Group Inc. lifted its stake in shares of U.S. Physical Therapy by 9,300.0% during the 3rd quarter. Bessemer Group Inc. now owns 9,400 shares of the company’s stock valued at $1,115,000 after buying an additional 9,300 shares in the last quarter. Stone Ridge Asset Management LLC lifted its stake in shares of U.S. Physical Therapy by 47.2% during the 3rd quarter. Stone Ridge Asset Management LLC now owns 3,973 shares of the company’s stock valued at $471,000 after buying an additional 1,274 shares in the last quarter. Crown Advisors Management Inc. lifted its stake in shares of U.S. Physical Therapy by 50.0% during the 3rd quarter. Crown Advisors Management Inc. now owns 15,000 shares of the company’s stock valued at $1,779,000 after buying an additional 5,000 shares in the last quarter. WINTON GROUP Ltd lifted its stake in shares of U.S. Physical Therapy by 1,288.8% during the 3rd quarter. WINTON GROUP Ltd now owns 116,066 shares of the company’s stock valued at $13,765,000 after buying an additional 107,709 shares in the last quarter. Finally, Cadence Capital Management LLC lifted its stake in shares of U.S. Physical Therapy by 20.1% during the 3rd quarter. Cadence Capital Management LLC now owns 12,290 shares of the company’s stock valued at $1,458,000 after buying an additional 2,053 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Several analysts have issued reports on USPH shares. Zacks Investment Research upgraded shares of U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research report on Tuesday, August 7th. TheStreet lowered shares of U.S. Physical Therapy from a “b” rating to a “c+” rating in a research report on Friday, November 2nd. Jefferies Financial Group restated a “hold” rating and set a $105.00 price target on shares of U.S. Physical Therapy in a research report on Friday, August 3rd. Barrington Research restated a “hold” rating on shares of U.S. Physical Therapy in a research report on Friday, August 3rd. Finally, Cantor Fitzgerald upped their price target on shares of U.S. Physical Therapy from $103.00 to $107.00 and gave the company a “neutral” rating in a research report on Friday, November 2nd. Four equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $113.67.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/u-s-physical-therapy-inc-usph-director-mark-j-brookner-sells-2000-shares.html.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Insider Buying and Selling by Quarter for U.S. Physical Therapy (NYSE:USPH)

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply